Zentalis Pharmaceuticals (ZNTL) Leases (2022 - 2025)
Zentalis Pharmaceuticals (ZNTL) has 4 years of Leases data on record, last reported at $30.2 million in Q3 2025.
- For Q3 2025, Leases fell 9.62% year-over-year to $30.2 million; the TTM value through Sep 2025 reached $30.2 million, down 9.62%, while the annual FY2024 figure was $32.5 million, 9.43% down from the prior year.
- Leases reached $30.2 million in Q3 2025 per ZNTL's latest filing, down from $31.2 million in the prior quarter.
- Across five years, Leases topped out at $43.6 million in Q1 2022 and bottomed at $30.2 million in Q3 2025.
- Average Leases over 4 years is $36.4 million, with a median of $35.9 million recorded in 2023.
- Peak YoY movement for Leases: decreased 15.52% in 2023, then dropped 6.87% in 2025.
- A 4-year view of Leases shows it stood at $42.4 million in 2022, then dropped by 15.24% to $35.9 million in 2023, then dropped by 9.43% to $32.5 million in 2024, then fell by 7.19% to $30.2 million in 2025.
- Per Business Quant database, its latest 3 readings for Leases were $30.2 million in Q3 2025, $31.2 million in Q2 2025, and $31.9 million in Q1 2025.